Heslop H E, Benaim E, Brenner M K, Krance R A, Stricklin L M, Rochester R J, Billing R
Division of Bone Marrow Transplantation, St Jude Children's Research Hospital, Memphis, TN 38101, USA.
Lancet. 1995 Sep 23;346(8978):805-6. doi: 10.1016/s0140-6736(95)91621-0.
Therapy of steroid-resistant graft-versus-host disease (GVHD) with antibodies to T cells or cytokines is of limited value because GVHD is mediated by a pleomorphic group of effective cells and cytokines. CBL-1, a murine monoclonal antibody, recognises an antigen on activated T cells, B cells, and natural killer cells. We administered CBL-1 to ten patients with grade III or IV steroid-resistant GVHD. Complete remissions occurred in five cases and partial remissions in four. The organ system(s) affected by GVHD was not a predictor of response. CBL-1 was well tolerated and did not exacerbate post-transplant immunodeficiency. Our findings support the use of CBL-1 in primary prophylaxis for GVHD.
使用针对T细胞或细胞因子的抗体治疗类固醇抵抗性移植物抗宿主病（GVHD）的价值有限，因为GVHD是由一群多形性的效应细胞和细胞因子介导的。鼠单克隆抗体CBL-1可识别活化的T细胞、B细胞和自然杀伤细胞上的一种抗原。我们对10例III级或IV级类固醇抵抗性GVHD患者给予了CBL-1。5例完全缓解，4例部分缓解。受GVHD影响的器官系统不是反应的预测指标。CBL-1耐受性良好，不会加重移植后免疫缺陷。我们的研究结果支持将CBL-1用于GVHD的一级预防。
